Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer.

Chunjing WuSydney A SpectorGeorge TheodoropoulosDan J M NguyenEmily Y KimAshley GarciaNiramol SavarajDiane C LimAnkita PaulLynn G FeunMichael BickerdikeMedhi Wangpaichitr

Published in: Cancer & metabolism (2023)

Our study reports the presence of platinum-resistant lung tumors that utilize both IDO1/TDO2 enzymes for survival, and to escape immune surveillance as a consequence of KYN metabolites. We also report early in vivo data in support of the potential therapeutic efficacy of the dual IDO1/TDO2 inhibitor AT-0174 as a part of immuno-therapeutic treatment that disrupts tumor metabolism and enhances anti-tumor immunity.

Keyphrases

public health
electronic health record
machine learning
adverse drug
climate change
drug induced